Staging of breast cancer: new recommended standard procedure.

Abstract:

BACKGROUND:Staging procedures used to detect metastatic breast cancer at the time of diagnosis are bone scan (BS), chest X-ray (CXR), liver ultrasonography (LUS) and laboratory parameters (LP). These procedures are expensive and not all patients need them. We aimed to identify groups of patients with different risks for metastatic disease. METHODS:We reviewed data from 1,218 consecutive cases of breast cancer. Pathological and biological parameters and instrumental procedures performed at the time of diagnosis and during 6 months of follow-up were recorded. True positive and negative, false positive and negative cases were evaluated. All cases were grouped on the basis of tumour size, nodal involvement, biological characteristics, menopausal status and age. RESULTS:We observed 46 (3.8%) true positive cases with metastatic disease at the time of diagnosis. Documentation relating to BS, CXR and LUS was available for 1,193, 1,206 and 1,206 patients, respectively, with 37 (3.1%), 8 (0.7%) and 10 (0.8%) true positive tests. Logistic regression analysis showed significant odds ratio estimates for pT status and nodal status, thus highlighting the role of these morphological data. These findings suggest that breast cancer patients can be divided into two subgroups: first group pT1-3N0-1. with < or = 3 involved nodes, and second group pT1-3N1 with > or = 4 involved nodes, pT4 and pN2 (metastases detection rate 1.46 and 10.68%, respectively). In the former group the appropriate procedures of staging would only be laboratory parameters, whereas in the latter group BS, CXR, LUS, LP and tumour markers CEA and CA 15.3 would.be necessary. CONCLUSIONS:The standard staging procedures to detect metastatic disease at breast cancer diagnosis require modification. On the basis of the literature data and our findings, the full staging procedure is appropriate in the second group of patients.

authors

Ravaioli A,Pasini G,Polselli A,Papi M,Tassinari D,Arcangeli V,Milandri C,Amadori D,Bravi M,Rossi D,Fattori PP,Pasquini E,Panzini I

doi

10.1023/a:1014900600815

subject

Has Abstract

pub_date

2002-03-01 00:00:00

pages

53-60

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

72

pub_type

杂志文章
  • Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.

    abstract::Mutations in breast cancer susceptibility genes, BRCA1 and BRCA2 account for more than 80% of hereditary breast and ovarian cancers. p53 tumor suppressor gene that controls cellular growth and differentiation is also known to be mutated in more than 50% of human cancers including breast cancer. We have carried out a s...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-0593-8

    authors: Hedau S,Jain N,Husain SA,Mandal AK,Ray G,Shahid M,Kant R,Gupta V,Shukla NK,Deo SS,Das BC

    更新日期:2004-11-01 00:00:00

  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract::Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005951125574

    authors: Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期:1998-03-01 00:00:00

  • Effect of false-positives and women's characteristics on long-term adherence to breast cancer screening.

    abstract::False-positive results may influence adherence to mammography screening. The effectiveness of breast cancer screening is closely related to adequate adherence among the target population. The objective of this study was to evaluate how false-positives and women's characteristics affect the likelihood of reattendance a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1581-4

    authors: Román R,Sala M,De La Vega M,Natal C,Galceran J,González-Román I,Baroja A,Zubizarreta R,Ascunce N,Salas D,Castells X

    更新日期:2011-11-01 00:00:00

  • Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.

    abstract::IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the E...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000032922.87541.31

    authors: Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

    更新日期:2004-07-01 00:00:00

  • Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

    abstract:PURPOSE:Peripheral blood lymphopenia and elevated neutrophil-to-lymphocyte ratio (NLR) have been associated with poor outcomes in various malignancies. However, existing literature has largely focused on baseline parameters. The aim of this study is to assess the impact of radiation therapy (RT) and chemotherapy on abs...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05106-7

    authors: Patel DA,Xi J,Luo J,Hassan B,Thomas S,Ma CX,Campian JL

    更新日期:2019-04-01 00:00:00

  • Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature.

    abstract::Angiosarcoma of the breast (AB) is a rare entity: its overall incidence is estimated at between 0.002% and 0.005% per year. Some potential risk factors have been described, mainly previous irradiation of the breast. We report the experience of the European Institute of Oncology with this unusual disease from January 1...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9429-z

    authors: Luini A,Gatti G,Diaz J,Botteri E,Oliveira E,Cecilio Sahium de Almeida R,Veronesi P,Intra M,Pagani G,Naninato P,Viale G

    更新日期:2007-09-01 00:00:00

  • Tumor markers and their significance in the management of breast cancer. Workshop, National Institutes of Health, March 6, 1985.

    abstract::The use of molecular components from both normal and neoplastic breast tissue as markers for breast tumors has long been recognized as of major potential for breast cancer diagnosis, and has been an area of active research. Recent developments in immunological approaches have further stimulated this field by permittin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806776

    authors: Ceriani R,Anderson EP

    更新日期:1985-01-01 00:00:00

  • Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.

    abstract::Docetaxel is primarily metabolized by CYP3A4 and susceptible to alterations in clearance by CYP3A4 inhibition and induction. Imatinib is a CYP3A4 inhibitor. A phase I study of docetaxel and imatinib in metastatic breast cancer (MBC) was conducted to test the hypothesis that imatinib decreased docetaxel clearance. Doce...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1413-6

    authors: Connolly RM,Rudek MA,Garrett-Mayer E,Jeter SC,Donehower MG,Wright LA,Zhao M,Fetting JH,Emens LA,Stearns V,Davidson NE,Baker SD,Wolff AC

    更新日期:2011-05-01 00:00:00

  • HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.

    abstract::This retrospective study investigates the correlation of intra-individual HER2 status between primary breast cancers and corresponding recurrences in a population derived cohort. The REMARK criteria were used as reference. In 151 breast cancer patients, primary tumors were analyzed for HER2 status on histopathology se...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1029-2

    authors: Wilking U,Karlsson E,Skoog L,Hatschek T,Lidbrink E,Elmberger G,Johansson H,Lindström L,Bergh J

    更新日期:2011-01-01 00:00:00

  • Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography.

    abstract::The transition from screen-film to digital mammography may have altered diagnostic evaluation of women following a positive screening examination. This study compared the use and timeliness of diagnostic imaging and biopsy for women screened with screen-film or digital mammography. Data were obtained from 35,321 posit...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-013-2466-5

    authors: Hubbard RA,Zhu W,Horblyuk R,Karliner L,Sprague BL,Henderson L,Lee D,Onega T,Buist DS,Sweet A

    更新日期:2013-04-01 00:00:00

  • Preclinical evaluation of nuclear morphometry and tissue topology for breast carcinoma detection and margin assessment.

    abstract::Prevention and early detection of breast cancer are the major prophylactic measures taken to reduce the breast cancer related mortality and morbidity. Clinical management of breast cancer largely relies on the efficacy of the breast-conserving surgeries and the subsequent radiation therapy. A key problem that limits t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0914-z

    authors: Nyirenda N,Farkas DL,Ramanujan VK

    更新日期:2011-04-01 00:00:00

  • Effect of social housing condition on heat shock protein (HSP) expression in the Shionogi mouse mammary carcinoma (SC115).

    abstract::Our previous studies have shown that social housing conditions can significantly alter the growth rate of the Shionogi mouse mammary carcinoma (SC115). The present study extended our investigations to the molecular level by examining stressor effects on the expression of a group of stress-responsive proteins, the heat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006314010958

    authors: Andrews HN,Kerr LR,Strange KS,Emerman JT,Weinberg J

    更新日期:2000-02-01 00:00:00

  • Chromosome 11q13 markers and D-type cyclins in breast cancer.

    abstract::One in six primary human breast cancers has DNA amplification centered on the cyclin D1 gene (CCND1) on chromosome 11q13. This genetic abnormality is preferentially associated with estrogen-receptor positive tumors and may define a sub-class of patients with an adverse prognosis. Although CCND1 has the credentials of ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00682720

    authors: Peters G,Fantl V,Smith R,Brookes S,Dickson C

    更新日期:1995-01-01 00:00:00

  • Droloxifene, a new antiestrogen: its role in metastatic breast cancer.

    abstract::Droloxifene, a new antiestrogen, has theoretical advantages over tamoxifen based on preclinical data. These include higher affinity to the estrogen receptor, higher antiestrogenic to estrogenic ratio, and more effective inhibition of cell growth and division in ER positive cell lines, as well as less toxicity, includi...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1007/BF00689679

    authors: Rauschning W,Pritchard KI

    更新日期:1994-01-01 00:00:00

  • Impact of self-reported data on the acquisition of multi-generational family history and lifestyle factors among women seen in a high-risk breast screening program: a focus on modifiable risk factors and genetic referral.

    abstract:BACKGROUND:The phrase "high-risk for breast cancer" is used to identify various groups at elevated cancer risk, and the appropriate surveillance and risk-reducing strategies differ based on the etiology of risk. Here, we review the utility of patient-reported data to capture women with modifiable lifestyle risk factors...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4115-x

    authors: Rosenberger LH,Weber R,Sjoberg D,Vickers AJ,Mangino DA,Morrow M,Pilewskie ML

    更新日期:2017-04-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract::The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0080-8

    authors: Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期:2009-05-01 00:00:00

  • Four cases of chylous fistula after breast cancer resection.

    abstract::Chylous fistulas in cases treated surgically for breast cancer only, are rare. We encountered four chylous fistula cases after breast cancer operations out of a total of 851 cases, all of which involved the left breast. Chylous fistulas were confirmed by axillary white fluid and were unrelated to obesity, surgical met...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/B:BREA.0000010675.87358.b6

    authors: Nakajima E,Iwata H,Iwase T,Murai H,Mizutani M,Miura S,Kato H

    更新日期:2004-01-01 00:00:00

  • Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.

    abstract:PURPOSE:Neutropenia is the most common toxicity of CDK4/6 inhibitors, causing frequent dose interruptions. However, CDK4/6 inhibitor-induced neutropenia shows a benign clinical course in contrast to that caused by chemotherapy. Here, we investigated the safety of a new dose scheme for palbociclib, which avoids dose del...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05750-y

    authors: Ham A,Kim MH,Kim GM,Kim JH,Kim JY,Park HS,Park S,Cho YU,Park BW,Kim SI,Sohn J

    更新日期:2020-08-01 00:00:00

  • Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

    abstract::Resistance to tamoxifen is a major clinical challenge in the treatment of breast cancer; however, it is still unclear which signaling pathways are the major drivers of tamoxifen-resistant growth. To characterize resistance mechanisms, we have generated different tamoxifen-resistant breast cancer cell lines from MCF-7....

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2485-2

    authors: Thrane S,Lykkesfeldt AE,Larsen MS,Sorensen BS,Yde CW

    更新日期:2013-05-01 00:00:00

  • Drug dosage intensity--a panel discussion.

    abstract::There is now widespread interest in the subject of drug dose intensity in cancer treatment. Recent retrospective analyses have shown a clear-cut benefit for those patients receiving either the intended drug dosage in a particular regimen or the highest dosage achievable through an escalation scheme. In this discussion...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807361

    authors: McGuire WL,Goldie J,Hryniuk W,Tormey DC

    更新日期:1987-01-01 00:00:00

  • Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen.

    abstract::The anti-estrogenic effect of tamoxifen is suggested to be mainly attributable to its metabolite (Z)-endoxifen, and a minimum therapeutic threshold for (Z)-endoxifen in serum has been proposed. The objective of this research was to establish the relationship between dried blood spot (DBS) and serum concentrations of t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-2999-2

    authors: Jager NG,Rosing H,Schellens JH,Beijnen JH,Linn SC

    更新日期:2014-07-01 00:00:00

  • EGF binding is quantitatively related to growth in node-positive breast cancer.

    abstract::Number of mitoses and EGF binding were determined in parallel in biopsies of 27 lymph-node positive and of 23 lymph-node negative breast cancer patients. For node-positive patients the parameters for cell growth and EGF binding were quantitatively correlated by the equation y = P3 + P1(1- exp(- P2x]. For node-negative...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805739

    authors: Spitzer E,Koepke K,Kunde D,Grosse R

    更新日期:1988-09-01 00:00:00

  • Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors.

    abstract::Elevated body weight is a risk factor for postmenopausal breast cancer and is associated with increased incidence of spontaneous and chemically induced mammary tumors (MTs) in rodents. In this study, genetically obese Lep(ob)Lep(ob) female mice that overexpress human TGF-alpha (transforming growth factor-alpha) were u...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1021891825399

    authors: Cleary MP,Phillips FC,Getzin SC,Jacobson TL,Jacobson MK,Christensen TA,Juneja SC,Grande JP,Maihle NJ

    更新日期:2003-02-01 00:00:00

  • Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project.

    abstract::The 2008 Physical Activity (PA) Guidelines recommend engaging in at least 2.5 h (10 MET-hours/week) of moderate intensity PA per week (defined as 4 METs) to reduce risk of morbidity and mortality. This analysis was conducted to investigate whether this recommendation can be extended to breast cancer survivors. Data fr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1770-1

    authors: Beasley JM,Kwan ML,Chen WY,Weltzien EK,Kroenke CH,Lu W,Nechuta SJ,Cadmus-Bertram L,Patterson RE,Sternfeld B,Shu XO,Pierce JP,Caan BJ

    更新日期:2012-01-01 00:00:00

  • Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands.

    abstract:PURPOSE:A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into invasive breast cancer. However, standard treatment consists of surgical excision. Trials aim to identify a subgroup of low-risk DCIS patients that can safely forgo surgical treatment based on histologic grade, which highligh...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05082-y

    authors: van Dooijeweert C,van Diest PJ,Willems SM,Kuijpers CCHJ,Overbeek LIH,Deckers IAG

    更新日期:2019-04-01 00:00:00

  • Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies.

    abstract::Evidence for an association between fruit and vegetable intake and breast cancer risk is inconclusive. To clarify the association, we conducted a systematic review and meta-analysis of the evidence from prospective studies. We searched PubMed for prospective studies of fruit and vegetable intake and breast cancer risk...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-012-2118-1

    authors: Aune D,Chan DS,Vieira AR,Rosenblatt DA,Vieira R,Greenwood DC,Norat T

    更新日期:2012-07-01 00:00:00

  • Weight changes after adjuvant treatment in Korean women with early breast cancer.

    abstract:BACKGROUND:Weight gain is a common problem in breast cancer patients and is reported to be associated with poorer survival. However, most data are limited to Western women. We evaluated weight changes after adjuvant treatment in Korean women with early breast cancer. METHODS:The authors reviewed the records of 260 pat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9984-6

    authors: Han HS,Lee KW,Kim JH,Kim SW,Kim IA,Oh DY,Im SA,Bang SM,Lee JS

    更新日期:2009-03-01 00:00:00

  • Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.

    abstract::The spectrum of germline mutations among Jewish non Ashkenazi high risk breast/ovarian cancer families includes a few predominant mutations in BRCA1 (185delAG and Tyr978X) and BRCA2 (8765delAG). A few additional recurring mutations [A1708E, 981delAT, C61G (BRCA1) R2336P, and IVS2 + 1G > A (BRCA2)] have been reported i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2006-8

    authors: Laitman Y,Simeonov M,Herskovitz L,Kushnir A,Shimon-Paluch S,Kaufman B,Zidan J,Friedman E

    更新日期:2012-06-01 00:00:00

  • Outcomes of a weight loss intervention among rural breast cancer survivors.

    abstract::Obese breast cancer survivors have increased risk of recurrence and death compared to their normal weight counterparts. Rural women have significantly higher obesity rates, thus weight control intervention may be a key strategy for prevention of breast cancer recurrence in this population. This one-arm treatment study...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-011-1922-3

    authors: Befort CA,Klemp JR,Austin HL,Perri MG,Schmitz KH,Sullivan DK,Fabian CJ

    更新日期:2012-04-01 00:00:00

  • Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines.

    abstract::We analyzed the p53 mutational status, mRNA and protein expression in 24 human breast carcinoma cell lines. Following measurement of their DNA content with flow cytometry, we ascertained the copy numbers of the centromere of chromosome 17 (cen17) and p53 with fluorescence in situ hybridization (FISH). A functional yea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1023351717408

    authors: Concin N,Zeillinger C,Tong D,Stimpfl M,König M,Printz D,Stonek F,Schneeberger C,Hefler L,Kainz C,Leodolter S,Haas OA,Zeillinger R

    更新日期:2003-05-01 00:00:00